Here’s a polished English translation of the Chinese title: **”Illumina Launches Mobile Bioinformatics Analysis Solution in China, Advancing Proteomics Ecosystem Collaboration”**

Shanghai June 18, 2026 /PRNewswire/ — Recently, Illumina officially launched the “Illumina Bio-IT Mobile Lab”, a bioinformatics analysis solution that adopts a mobile deployment model, designed to deliver high-performance computing power driven by DRAGEN™ directly to the front lines of scientific and clinical research. Concurrently, Illumina has further strengthened its proteomics ecosystem partnerships in mainland China.

In large-scale population genomic studies and high-timeliness multi-center clinical trial scenarios, traditional bioinformatics infrastructure deployment faces dual challenges of data localization compliance requirements and deployment efficiency, which constrain the enhancement of bioinformatics analysis capabilities at the research front. Against this backdrop, the “Illumina Bio-IT Mobile Lab” enables high-performance computing power to “move with scientific and clinical research needs.”

As the first-of-its-kind mobile bioinformatics analysis platform in China, the Illumina Bio-IT Mobile Lab helps customers accelerate the transformation from sequencing data to scientific insights. Centered on the DRAGEN™ ultra-fast omics analysis platform, it integrates internationally standardized multi-omics and intelligent bioinformatics analysis software, flexibly deploying high-precision omics analysis capabilities—traditionally reliant on fixed data centers—to the sites of scientific and clinical research. This solution not only supports complex application scenarios such as whole-genome, oncology, pharmacogenomics, and multi-omics, but also ensures security compliance and analysis efficiency based on efficient local data processing.

“Illumina has always adhered to a customer-centric philosophy to serve local customers,” said Zheng Lei, Illumina Senior Vice President and General Manager of Greater China. “Through bioinformatics analysis and cutting-edge multi-omics solutions that are closer to frontline needs, as well as continuously expanding local ecosystem collaborations, Illumina aims to support the more efficient transformation of multi-omics data into insights serving scientific and clinical research. We also look forward to joining hands with more Chinese industry, academia, and research partners to continuously advance the development of precision medicine-related research and applications.”

This solution was meticulously developed by Illumina, with professional advice from Professor Ye Kai’s team at Xi’an Jiaotong University during the R&D process, deeply integrating high-performance computing, mature standardized analysis workflows, and bioinformatics expert support:

• Core Engine Widely Adopted by Global Large-Scale Cohort Projects: The core computing engine of the Illumina Bio-IT Mobile Lab, DRAGEN, is widely used by numerous national-level genomics projects worldwide, including the UK Biobank and Singapore’s PRECISE-SG100K population health study.
• Innovative Solutions and Full-Process Analysis Support: Built-in latest multi-omics and intelligent software packages provide full-process solutions for scientific and clinical research customers.
• Scalable High-Performance Computing Capability: Offers high-performance mobile computing power, scarce in China, to customers in fields such as genetics, oncology, and drug development, capable of completing analysis of over 2,500 human whole-genome datasets at 30X sequencing depth^[1] within one week.
• Local Deployment and Compliance Assurance: Data analysis is conducted at the customer’s site, fully complying with national data compliance requirements.

The China Council of the International Society for Computational Biology (ISCB-China) and representatives from the Drug Information Association (DIA) China jointly witnessed this launch, reflecting broad consensus from academia and industry to further enhance the accessibility of bioinformatics capabilities.

Concurrently, Illumina completed the signing of its first batch of “Strategic Partners” and “Intended Partners” in proteomics in mainland China. This marks the first collective appearance of proteomics local ecosystem partners following Illumina’s acquisition of SomaLogic. In the future, customers can benefit from the integrated capabilities of Illumina SomaSeq™ Discovery, SomaScan™ solutions, DRAGEN, and Illumina Connected Multiomics, enabling large-scale generation of rich multi-omics datasets and flexible selection of tools and workflows best suited to their needs.

About Illumina                                           

Illumina is dedicated to improving human health by unlocking the power of genomics. Our focus on innovation has made us a global leader in DNA sequencing and array technologies, serving customers in the research, clinical, and applied markets worldwide. Our products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, please visit www.illumina.com.cn or follow Illumina’s WeChat official account.